| Value | ₹350.0 Cr |
|---|---|
| Execution period | December 2027 |
| manufacturing capacity | 6000.0 MTPA |
NSE filing, NSE: IOLCP. Summary written from the filing by ALFA Finder's alert engine.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹184.93
- Market cap
- ₹5,428 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 32.3×Sector 48.7×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
IOL Chemicals and Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
IOL Chemicals and Pharmaceuticals Regulatory Approval
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Other Announcement
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
- Call
- Guides 20% growth
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹495 Cr Investment
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
- Value
- ₹495.0 Cr
- ibuprofen manufacturing capacity
- 6000 MTPA
Other capacity expansion announcements
All →Patel Retail Capacity Expansion: ₹2 Cr Investment
Patel Retail will add 20,000 sq ft at its 100%-utilised Ambernath distribution centre. The Rs.2 Crore investment is funded by internal accruals.
- Value
- ₹2.00 Cr
- Execution
- Within approximately 15-20 days from the date of intimation
- distribution centre covered space
- 20000.0 sq ft
Aditya Vision Capacity Expansion
Aditya Vision opened five new showrooms, taking its total to 219. The expansion enters Madhya Pradesh and West Bengal, its fifth and sixth states.
- new showrooms
- 5.0 showrooms
FlySBS Aviation Capacity Expansion: ₹13.98 Cr Investment
FlySBS Aviation will induct a Hawker 900XP 9-seater aircraft in October 2026, funded by Rs.13.98 Crore from IPO proceeds. Fleet rises from two to three aircraft.
- Value
- ₹13.98 Cr
- Execution
- October 2026
- fleet capacity (9-seater aircraft)
- 1.0 aircraft
Greenply Industries Capacity Expansion: ₹30 Cr Investment
Greenply's board approved further investment of up to INR 30 crore in its wholly owned subsidiary Greenply Sandila Private Limited for plywood capacity expansion. The funds will be paid in one or more tranches by Q4 FY2028.
- Value
- ₹30.00 Cr
- Execution
- Q4 of FY 2028, in one or more tranches
Ethos Capacity Expansion
Ethos has opened a new Ethos Summit boutique at Fort, Mumbai, taking its total to 105 boutiques across India. The filing is an update on a store opening with no monetary value disclosed.
- new boutiques
- 1.0 boutiques
Greenply Industries Capacity Expansion
Greenply's board noted a 15 million sq mtr plywood capacity expansion at subsidiary Greenply Sandila, due by Q4 FY2028. Approximately Rs. 125 crore investment is planned.
- Execution
- By Q4 of FY 2028
- plywood manufacturing capacity
- 15.0 million sq mtr